bloodtypeGLP-1 + Co-Condition

GLP-1s with Type 2 Diabetes

GLP-1 receptor agonists were diabetes drugs first and weight-loss drugs second. Here is how they handle the two problems simultaneously, what to expect on A1c, and how the diabetes versions differ from the obesity ones.

The short answer

GLP-1 medications were developed for type 2 diabetes and remain among the most effective non-insulin glucose-lowering drugs available. Semaglutide (Ozempic) and tirzepatide (Mounjaro) are both FDA-approved for T2D, deliver A1c reductions of 1.5–2.4 percentage points, and produce meaningful weight loss as a bonus. They rarely cause hypoglycemia on their own. For patients managing T2D and obesity together, they have become first-line for many treatment guidelines, including the 2025 ADA Standards of Care.

What the research shows

In the SUSTAIN trial program, once-weekly semaglutide produced mean A1c reductions of roughly 1.4–1.8 percentage points across doses, with the 2.0 mg dose (added in 2022) reaching the higher end. Weight loss averaged 4–6 kg at the diabetes doses. The drug also reduced cardiovascular events in patients with established CV disease in SUSTAIN-6, which led to the cardiovascular indication for Ozempic.

Tirzepatide raised the bar in the SURPASS trials. Across SURPASS 1–5, the highest dose (15 mg) produced A1c reductions of 2.0–2.4 percentage points and weight loss of 9–12 kg — both significantly larger than comparators, including injectable semaglutide and basal insulin. In SURPASS-2, head-to-head against semaglutide 1.0 mg in T2D, tirzepatide produced both greater A1c reduction and greater weight loss at every dose. The dual GIP/GLP-1 mechanism appears to give it an edge.

Hypoglycemia risk is low when GLP-1s are used as monotherapy or with metformin. The drugs work in a glucose-dependent way — they stimulate insulin secretion only when blood glucose is elevated — which is why they rarely cause lows on their own. The risk rises sharply when combined with insulin or sulfonylureas (glipizide, glyburide), where the other drug's mechanism is not glucose-dependent. Most diabetes specialists reduce insulin or sulfonylurea doses by 10–30% when starting a GLP-1.

Cardiovascular and renal outcomes have shifted the indication. Multiple GLP-1s now carry cardiovascular indications in T2D — semaglutide, liraglutide, dulaglutide — based on outcomes trials showing roughly 12–26% reduction in major adverse cardiovascular events. The FLOW trial (semaglutide in T2D with chronic kidney disease) showed a 24% reduction in kidney disease progression. These extra-glycemic benefits are now part of why the ADA recommends GLP-1s early in T2D management, not just as a third-line glucose-lowering option.

How it tends to work in practice

For a newly diagnosed T2D patient, the typical entry point is metformin plus a GLP-1, either started together or sequentially within the first few months. Semaglutide (Ozempic) and tirzepatide (Mounjaro) are the most commonly prescribed. Doses are titrated up over 16–20 weeks, the same titration schedule used in the obesity versions, but the target dose is often the middle of the range (1.0 mg semaglutide, 7.5–10 mg tirzepatide) rather than the maximum.

A1c response is usually visible by month 3 — many patients see drops of 1.0–1.5 percentage points by the first follow-up labs. Patients on insulin frequently need significant insulin reductions in the first weeks; some are eventually able to come off mealtime insulin entirely. Patients on sulfonylureas often have those discontinued within a month or two. The diabetes team should be involved in this de-prescribing process to avoid lows.

The diabetes-labeled product versus the obesity-labeled product is mostly a labeling and dose distinction, not a chemistry one. Ozempic and Wegovy are both semaglutide; Wegovy is dosed to 2.4 mg weekly for obesity. Mounjaro and Zepbound are both tirzepatide; the dose range is the same. Insurance often only covers the diabetes-labeled product for patients with a T2D diagnosis, which can affect the practical choice but not the underlying drug.

Key considerations

vaccines

Watch sulfonylureas and insulin

On its own, a GLP-1 rarely causes hypoglycemia. Combined with insulin or sulfonylureas, the risk jumps. Expect your team to reduce those doses 10–30% at the start.

favorite

Outcomes go beyond A1c

GLP-1s in T2D reduce cardiovascular events and slow kidney disease progression, independent of glucose control. That's why the ADA recommends them early, not just for A1c numbers.

monitoring

Re-check labs at 3 months

Most teams pull A1c, kidney function, and a lipid panel at 3 months. Expect a 1.0–1.5 percentage point drop in A1c if you've reached a therapeutic dose and are tolerating the drug.

Common questions

Common Concerns

Should I switch from Ozempic to Mounjaro for better A1c control?expand_more

SURPASS-2 directly compared tirzepatide to semaglutide 1.0 mg in T2D and found tirzepatide produced larger A1c reductions at every dose. If A1c is not at goal on a maximum semaglutide dose, switching to tirzepatide is a reasonable next step. Insurance coverage and side-effect tolerance often drive the actual decision.

Will a GLP-1 cause hypoglycemia?expand_more

Rarely on its own, because the drugs only stimulate insulin secretion when glucose is elevated. The risk increases when combined with insulin or sulfonylureas (glipizide, glyburide). If you're on either, your provider should reduce those doses when you start a GLP-1.

Can I stop my other diabetes meds when I start a GLP-1?expand_more

Usually not all at once. Metformin is typically continued. Insulin and sulfonylureas are often reduced or eventually stopped as A1c improves, but this needs to be managed by your prescriber over weeks to months, with glucose monitoring.

How much weight will I lose on the diabetes dose?expand_more

Less than on the obesity dose. At Ozempic 1.0 mg, average weight loss is 4–6 kg over 6–12 months. At Mounjaro 10–15 mg, average is 7–12 kg. The obesity-labeled doses (Wegovy 2.4 mg, Zepbound 15 mg) produce larger losses but require the obesity indication for coverage.

Does a GLP-1 cure type 2 diabetes?expand_more

No. It can drive A1c into the non-diabetic range and allow significant medication de-escalation, but stopping the GLP-1 typically leads to glucose rising back over months. T2D is managed, not cured, on these drugs — though sustained weight loss and metabolic improvement on therapy can shift the disease meaningfully in many patients.

Keep exploring

Browse all GLP-1 guides.